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Mouse islets {not used for respiration), kidneys and liver were studied in early and manifest alloxan diabetes, 
and in genetic diabetes. In these organs the mito~hondrial aconitase activity was lower, state 3 respiration 
with citrate or pyruvate plus malate (but not with succinate) was decreased, and the concentration of citrate 
was increased, compared with non-diabetic control mice. The alterations suggest a role of lowered activity 
of mitochondrial aconitase in alloxan diabetes, and probably also in genetic diabetes. 
Aconitase Alloxan Citrate Diabetes Mitochondria Respiration 
1. INTRODUCTION 
Preceding in vivo and in vitro studies, mainly 
directed to liver, kidneys and islets, have disclosed 
that alloxan is taken up in mitochondria [ 1 ,Z], and 
alters their structure and function [3--51. These 
changes may be due to inhibition of mitochondrial 
aconitase, since it has recently been reported for 
the first time that alloxan induces marked decrease 
of the activity of that enzyme in vitro 161, and since 
alloxan inhibits mitochondrial respiration, most 
efficiently when the substrate is citrate or pyruvate 
plus malate, less efficiently when isocitrate, (Y- 
ketogiutarate, glutamate and malate are the 
substrates, and with least effect when the respira- 
tion is supported by succinate [4,5,7]. A similar 
substrate dependence has been observed for the ef- 
fect of alloxan on the volume and retention of ac- 
cumulated Ca2+ in isolated mitochondria [7]. 
The aim of this work was to study whether the 
activity of mitochondrial aconitase is inhibited in 
early and manifest alloxan diabetes, and/or in 
genetic diabetes. In addition to measurement of 
aconitase activity, the mitochondrial oxygen con- 
sumption was studied using different substrates, 
and the tissue concentration of citrate was deter- 
mined, since these might be altered if the 
mitochondrial aconitase activity is decreased. 
2. MATERIALS AND METHODS 
As in preceding studies [l&S], the animals were 
from locai stocks of non-diabetic (C57BL- 
KsJ-+ / + and ob/ub) and genetically diabetic 
(C57BL-&J-@/&J) mice of both sexes; the ob/ob 
mice being used as controls and for induction of 
alloxan diabetes for islet studies, and the’ + /+ 
mice being used for the same purpose for liver and 
kidney studies. Alloxan, 200 mg/kg body wt, or 
saline (controls) was injected i.p. in fasted (21 h) 
mice, which were allowed to eat again 4 h after the 
injections. The db/db mice were studied in the late 
stage of the disease [8,9]. Blood glucose was 
checked in all mice. 
The liver, kidneys and islets, isolated by the col- 
lagenase technique [1,5,8], were studied. The 
mitochondrial aconitase activity was determined as 
previously described (without activation) [6]. The 
oxygen consumption of isolated mitochondria was 
determined at 2YC with a Clark-type electrode 
and 1 mg mitochondriaf protein/ml, in a medium 
containing 200 mM sucrose, 10 mM Hepes, 
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50 mM KCl, 4 mM MgC12 and 3 mM Pi (pH 7.2), 
in the presence (in combination with succinate) or 
absence of 1 pM rotenone. 
The concentration of citrate was determined en- 
zymatically, using instant freezing in situ for liver 
and kidneys, and (for technical reasons) using 
freeze-dried specimens of islets according to [lo]. 
Protein was measured spectrophotometrically. 
3. RESULTS 
No significant difference in the activity of 
mitochondrial aconitase was observed between fed 
and fasted control mice. Compared with non- 
diabetic control mice, the mitochondrial aconitase 
activity was significantly lower in the liver, kidneys 
and islets in early and manifest alloxan diabetes, 
and a less marked, although significant, decrease 
in enzymatic activity was found in all organs 
studied in genetic diabetes (table 1). 
The oxygen consumption could not be adequate- 
ly measured in islet mitochondria. No significant 
difference was seen between fed and fasted control 
mice. State 3 respiration with pyruvate plus malate 
(table 2) or with citrate (not shown in table) was 
significantly decreased in the liver and kidneys in 
Table 1 
Mitochondrial aconitase activity in mice with genetic diabetes, and in those with experimental diabetes 
in which the tissues were sampled at different intervals after the injection of alloxan 
Animal group; 
interval after 
injection 
lo3 x spec. act. (AAzde.rng protein-’ .min-‘) 
Liver Kidneys Islets 
Controls 29.5 f 2.3 (14) 45.5 + 2.7 (14) 39.4 f 4.4 (3) 
Alloxan, 10 min 8.9 +_ 4.0 ( 4)’ 21.0 * 5.1 ( 4)C - 
Alloxan, 1 h 10.1 f 3.9 ( 6)’ 18.4 f 5.1 ( 6)’ 11.0 of: 5.6 (3)b 
Alloxan, 2-4 days 14.7 + 3.7 ( 6)b 26.5 ? 4.3 ( 6)b 23.5 + 4.7 (3)b 
Controls 33.4 ?z 3.7 ( 7) 49.0 of: 4.2 ( 7) 46.0 Y!Z 3.7 (3) 
db/db 19.8 +_ 4.8 ( 7)a 24.2 + 6.7 ( 7)a 28.0 + 6.1 (3)a 
The substrate is 1 mM citrate, the figures are means k SE and the number of observations is given in 
brackets. Statistical difference from corresponding control values by Student’s f-test: a p < 0.05, b p < 
0.01 and ’ p < 0.001. Details are given in the text 
Table 2 
Oxygen consumption in liver and kidney mitochondria of mice with genetic diabetes or alloxan diabetes 
Animal group; 
interval after 
injection 
Substrate ngatom 0. min- ’ . mg protein-’ 
Liver Kidneys 
State 3 State 4 State 3 State 4 
Controls 
Controls 
Alloxan, 1 h 
Alloxan, 1 h 
Alloxan, 2-4 days 
Alloxan, 2-4 days 
Controls 
Controls 
db/db 
db/db 
P+M 
S 
P+M 
S 
P+M 
S 
P+M 
S 
P+M 
S 
70.9 * 5.1 (9) 18.3 -t 3.3 (9) 
145.1 + 23.4 (8) 34.7 + 4.9 (8) 
25.1 -+ 5.1 (4) 20.6 +- 4.5 (4) 
123.5 + 18.9 (4) 41.2 + 4.7 (4) 
47.1 * 4.3 (5)b 17.8 +_ 4.0 (5) 
132.0 + 24.9 (4) 39.0 f 5.1 (4) 
65.0 * 5.5 (6) 21.0 -t 4.0 (6) 
138.9 it_ 18.5 (6) 32.4 -c 4.3 (6) 
31.3 ? 4.0 (6)’ 18.0 f 3.9 (6) 
125.4 + 19.9 (6) 36.4 + 3.8 (6) 
62.5 f 4.8 (8) 14.9 +_ 3.8 (8) 
131.4 * 18.1 (7) 35.4 +_ 6.1 (7) 
17.4 + 4.8 (3)C 10.0 f 4.4 (3) 
100.5 -t 10.1 (3) 40.9 ? 5.6 (3) 
27.6 -+ 5.1 (5)’ 12.8 2 3.9 (5) 
107.7 s 9.5 (4) 33.3 -t 8.1 (4) 
58.4 f 5.1 (3) 15.7 * 4.4 (3) 
139.8 f 21.0 (3) 21.4 it_ 2.1 (3) 
21.8 + 4.0 (3)b 12.5 + 3.8 (3) 
131.1 +_ 17.5 (3) 38.4 f 6.5 (3) 
The substrates are 1 mM pyruvate (P), malate (M) and succinate (S). Details as in table 1 and in the text 
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Table 3 
Concentration of citrate in liver, kidneys @mol/lOO g wet wt) and islets ~mo1/100 g dry wt) of mice with 
genetic or alloxan diabetes 
Animal group; 
interval after 
injection 
Fed (F)/ 
starved (S) 
Controls 
Alloxan, 1 h 
Controls 
Alloxan, 2-4 days 
Controls 
db/db 
Liver Kidneys Islets 
61.4 + 7.4 (5) 44.5 + 5.1 (5) 59.8 * 6.3 (3) 
98.9 * 9.6 (5)” 126.7 2 8.4 (5)’ 173.5 * 17.1 (3)c 
31.3 -t 4.8 (7) 41.3 + 4.4 (7) 63.6 + 6.9 (3) 
70.2 + 9.0 (5)b 94.7 + 8.4 (5)’ 108.7 + 11.5 (3)’ 
36.2 + 5.9 (6) 49.8 + 5.2 (6) 68.4 -t 8.8 (3) 
67.0 -t 6.1 (7)b 104.5 f 9.0 (7)c 115.0 f 12.8 (3)b 
Details as in table 1 and in the text 
early and manifest alloxan diabetes and in genetic 
diabetes. In contrast, no significant difference was 
seen in state 3 respiration with succinate, or in state 
4 respiration with pyruvate plus malate, citrate or 
succinate. 
Since the concentration of citrate in the liver of 
fasted control mice was significantly @ < 0.05) 
higher than that in fed controls, differentiation has 
been made in table 3 between fed and fasted mice. 
No such difference was found in the kidneys or 
islets. The concentration of citrate in liver, kidneys 
and islets was significantly increased in early and 
manifest alloxan diabetes and in genetic diabetes. 
4. DISCUSSION 
Preceding in vitro studies indicated that alloxan 
inhibits the activity of mitochondrial aconitase in 
liver, kidneys and islets [6,7], and the present 
observation of lower activity of this enzyme in the 
same organs both in the early and the manifest 
stages of alloxan diabetes, than in non-diabetic 
control mice, suggests that alloxan also inhibits 
mitochondrial aconitase in vivo. Interestingly, 
diabetic symptoms have been reported in animals 
poisoned with the aconitase inhibitor fluorocitrate 
[I 1,121, although symptoms from the nervous 
system and heart usually predominate [13]. 
A consequence of in vivo inhibition of 
mitochondrial aconitase, e.g., by fluorocitrate, is 
accumulation of citrate in different organs, in- 
cluding liver, kidneys and whole pancreas [14- 161. 
The present finding of increased tissue concentra- 
tion of citrate therefore lends support to the view 
of inhibition by alloxan of mitochondrial 
aconitase. It should also be noted that there are 
reports on citrate accumulation in diabetic condi- 
tions, although the cause has not been elucidated. 
Thus, increased concentration of citrate has been 
found, e.g., in liver and whole pancreas in alloxan 
diabetes [ 16,171, and in endocrine pancreas in 
obese hyperglycemic mice [lo]. 
The in vitro effects of alloxan on oxygen con- 
sumption, transport and retention of ions, mem- 
brane potential and volume of liver, kidney and 
islet mitochondria are highly dependent on the 
substrate used [4,5,7], and the present data in- 
dicate that this also pertains to the mitochondrial 
oxygen consumption both in mice treated with 
alloxan in vivo and in mice with genetic diabetes. 
Thus, state 3 respiration with citrate or with 
pyruvate plus malate was decreased in liver and 
kidney mitochondria, compared with those from 
non-diabetic controls, whereas state 3 respiration 
with succinate was not significantly altered. Using 
higher concentrations of alloxan in vitro, than 
those supposed to result from in vivo administra- 
tion, some alterations were also observed in state 
3 respiration with succinate and in state 4 respira- 
tion with different substrates [4,5,7]. Interestingly, 
fluorocitrate has been reported to be a potent in- 
hibitor of the oxidation of citrate in liver 
mitochondria, with marked effect on state 3, but 
only slight effect on state 4 [18], and depressed 
state 3 respiration with pyruvate plus malate, but 
unaffected state 3 respiration with succinate, has 
been found in heart mitochondria of genetically 
diabetic mice [19]. 
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The occurrence of a substrate dependence, with 
highest sensitivity to alloxan in mitochondria 
respiring on citrate or on pyruvate plus malate, is 
consistent with in~bition of mitochondria~ 
aconitase. Moreover, the existence of similar 
aiterations in aconitase activity, oxygen consump- 
tion and concentration of citrate in mice with ex- 
perimental diabetes and in those with the genetic 
disease, suggests imilar, although not necessarily 
identical, diabetogenic mechanism(s) in these kinds 
of diabetes. 
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